13th May 2015 08:14
LONDON (Alliance News) - EKF Diagnostics Holdings PLC on Wednesday said its Selah Genomics subsidiary has launched the PrecisionPath next-generation sequencing technology in partnership with US cancer institute Greenville Health Systems.
The product will give patients wider access to affordable next-generation sequencing testing to help doctors in determining the more effective cancer treatment based on a patient's genetic profile, EKF said.
"It remains our goal to secure reimbursement from public and private payers for PrecisionPath? and we believe our case is strengthened by our focus on invasive colon cancer and the very clear guidelines that support clinical utility in this area," said EKF Chief Executive Julian Baines.
EKF shares were up 2.1% to 24.00 pence Wednesday morning.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Ekf Diagnostics